AstraZeneca PlcOTCPK - Current
Thu, Jul. 28, 5:50 AM
Aug. 19, 2014, 4:45 AM
- AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.
- Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.
- AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.